IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma

Autor: PR Newswire
Zdroj: PR Newswire US. 10/17/2023.
Abstrakt: SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announces the publication of the abstract for a proffered paper session at the European Society of Medical Oncology Congress 2023 (ESMO 2023) relating to selected clinical data from the company's ongoing Phase 2 clinical trial evaluating darovasertib in combination with crizotinib in patients having metastatic uveal melanoma (MUM). [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje